Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
MDXG's Cash-to-Debt is ranked higher than
90% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.55 vs. MDXG: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
MDXG' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.6  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.69
MDXG's Equity-to-Asset is ranked higher than
61% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. MDXG: 0.69 )
Ranked among companies with meaningful Equity-to-Asset only.
MDXG' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.44  Med: 0.8 Max: 0.87
Current: 0.69
0.44
0.87
Interest Coverage 54.41
MDXG's Interest Coverage is ranked lower than
54% of the 222 Companies
in the Global Medical Devices industry.

( Industry Median: 86.37 vs. MDXG: 54.41 )
Ranked among companies with meaningful Interest Coverage only.
MDXG' s Interest Coverage Range Over the Past 10 Years
Min: 54.41  Med: 283.3 Max: No Debt
Current: 54.41
Piotroski F-Score: 6
Altman Z-Score: 12.38
Beneish M-Score: -2.61
WACC vs ROIC
6.17%
12.86%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 7.53
MDXG's Operating Margin % is ranked higher than
62% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 2.62 vs. MDXG: 7.53 )
Ranked among companies with meaningful Operating Margin % only.
MDXG' s Operating Margin % Range Over the Past 10 Years
Min: -1334.98  Med: -4.46 Max: 13.01
Current: 7.53
-1334.98
13.01
Net Margin % 4.89
MDXG's Net Margin % is ranked higher than
60% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 1.55 vs. MDXG: 4.89 )
Ranked among companies with meaningful Net Margin % only.
MDXG' s Net Margin % Range Over the Past 10 Years
Min: -1447.4  Med: -6.95 Max: 15.72
Current: 4.89
-1447.4
15.72
ROE % 9.98
MDXG's ROE % is ranked higher than
70% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. MDXG: 9.98 )
Ranked among companies with meaningful ROE % only.
MDXG' s ROE % Range Over the Past 10 Years
Min: -276.61  Med: -48.04 Max: 29.85
Current: 9.98
-276.61
29.85
ROA % 6.92
MDXG's ROA % is ranked higher than
74% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 0.06 vs. MDXG: 6.92 )
Ranked among companies with meaningful ROA % only.
MDXG' s ROA % Range Over the Past 10 Years
Min: -557.14  Med: -41.9 Max: 24.02
Current: 6.92
-557.14
24.02
ROC (Joel Greenblatt) % 33.38
MDXG's ROC (Joel Greenblatt) % is ranked higher than
79% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 4.26 vs. MDXG: 33.38 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MDXG' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2458.54  Med: -485 Max: 71.75
Current: 33.38
-2458.54
71.75
3-Year Revenue Growth Rate 52.40
MDXG's 3-Year Revenue Growth Rate is ranked higher than
97% of the 237 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. MDXG: 52.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MDXG' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 26.2 Max: 261.7
Current: 52.4
0
261.7
GuruFocus has detected 6 Warning Signs with MiMedx Group Inc $MDXG.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MDXG's 10-Y Financials

Financials (Next Earnings Date: 2017-04-28)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

MDXG Guru Trades in Q1 2016

Jim Simons 85,500 sh (+336.22%)
Steven Cohen Sold Out
Paul Tudor Jones 34,800 sh (-4.66%)
» More
Q2 2016

MDXG Guru Trades in Q2 2016

Steven Cohen 150,000 sh (New)
Joel Greenblatt 15,559 sh (New)
Jim Simons Sold Out
Paul Tudor Jones 17,800 sh (-48.85%)
» More
Q3 2016

MDXG Guru Trades in Q3 2016

Joel Greenblatt 61,422 sh (+294.77%)
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
» More
Q4 2016

MDXG Guru Trades in Q4 2016

Paul Tudor Jones 18,000 sh (New)
John Hussman 70,000 sh (New)
Joel Greenblatt 25,283 sh (-58.84%)
» More
» Details

Insider Trades

Latest Guru Trades with MDXG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339113    SIC: 3841
Compare:NAS:SPNC, NAS:BABY, NYSE:ITGR, NAS:CNMD, NAS:VASC, NAS:CYNO, OTCPK:IOBCF, NAS:INGN, NAS:CSII, NAS:KTWO, NAS:OFIX, OTCPK:SBMAF, OTCPK:MZRTF, OTCPK:NHNKY, NAS:GNMK, NYSE:CRY, OTCPK:NMRD, NAS:XENT, NAS:VRAY, NAS:ARAY » details
Traded in other countries:MXE.Germany,
Headquarter Location:USA
MiMedx Group Inc is a developer, manufacturer and marketer of patent-protected regenerative biomaterial products and bioimplants processed from human amniotic membrane.

MiMedx Group Inc was incorporated in Florida on February 28, 2008. The company is an integrated developer, processor and marketer of patent protected and proprietary regenerative biomaterial products and bioimplants processed from human placental tissue, skin and bone. It supplies amniotic tissue products, having supplied allogrsfts in Wound Care, Burns, Surgery, Orthopedics, Spine, Sports Medicine, Ophthalmology and Dentistry.

Ratios

vs
industry
vs
history
PE Ratio 104.73
MDXG's PE Ratio is ranked lower than
86% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 27.53 vs. MDXG: 104.73 )
Ranked among companies with meaningful PE Ratio only.
MDXG' s PE Ratio Range Over the Past 10 Years
Min: 28.08  Med: 65.77 Max: 1843.33
Current: 104.73
28.08
1843.33
Forward PE Ratio 38.17
MDXG's Forward PE Ratio is ranked lower than
78% of the 111 Companies
in the Global Medical Devices industry.

( Industry Median: 21.79 vs. MDXG: 38.17 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 104.73
MDXG's PE Ratio without NRI is ranked lower than
86% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 27.51 vs. MDXG: 104.73 )
Ranked among companies with meaningful PE Ratio without NRI only.
MDXG' s PE Ratio without NRI Range Over the Past 10 Years
Min: 28.08  Med: 65.77 Max: 1843.33
Current: 104.73
28.08
1843.33
Price-to-Owner-Earnings 360.00
MDXG's Price-to-Owner-Earnings is ranked lower than
95% of the 107 Companies
in the Global Medical Devices industry.

( Industry Median: 32.96 vs. MDXG: 360.00 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
MDXG' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 125.48  Med: 215.35 Max: 3003.33
Current: 360
125.48
3003.33
PB Ratio 9.48
MDXG's PB Ratio is ranked lower than
84% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 3.11 vs. MDXG: 9.48 )
Ranked among companies with meaningful PB Ratio only.
MDXG' s PB Ratio Range Over the Past 10 Years
Min: 5.63  Med: 9.59 Max: 22
Current: 9.48
5.63
22
PS Ratio 5.28
MDXG's PS Ratio is ranked lower than
64% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. MDXG: 5.28 )
Ranked among companies with meaningful PS Ratio only.
MDXG' s PS Ratio Range Over the Past 10 Years
Min: 3.57  Med: 10.28 Max: 825
Current: 5.28
3.57
825
Price-to-Free-Cash-Flow 68.98
MDXG's Price-to-Free-Cash-Flow is ranked lower than
82% of the 112 Companies
in the Global Medical Devices industry.

( Industry Median: 27.61 vs. MDXG: 68.98 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
MDXG' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 46.65  Med: 77.05 Max: 191.73
Current: 68.98
46.65
191.73
Price-to-Operating-Cash-Flow 50.31
MDXG's Price-to-Operating-Cash-Flow is ranked lower than
82% of the 140 Companies
in the Global Medical Devices industry.

( Industry Median: 20.26 vs. MDXG: 50.31 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
MDXG' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 34.02  Med: 55.45 Max: 1830
Current: 50.31
34.02
1830
EV-to-EBIT 55.40
MDXG's EV-to-EBIT is ranked lower than
88% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 24.54 vs. MDXG: 55.40 )
Ranked among companies with meaningful EV-to-EBIT only.
MDXG' s EV-to-EBIT Range Over the Past 10 Years
Min: -618.7  Med: -6.7 Max: 1158.8
Current: 55.4
-618.7
1158.8
EV-to-EBITDA 42.07
MDXG's EV-to-EBITDA is ranked lower than
85% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 19.31 vs. MDXG: 42.07 )
Ranked among companies with meaningful EV-to-EBITDA only.
MDXG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -809.7  Med: -7 Max: 994.2
Current: 42.07
-809.7
994.2
Current Ratio 2.49
MDXG's Current Ratio is ranked higher than
52% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 2.38 vs. MDXG: 2.49 )
Ranked among companies with meaningful Current Ratio only.
MDXG' s Current Ratio Range Over the Past 10 Years
Min: 0.07  Med: 3.61 Max: 14
Current: 2.49
0.07
14
Quick Ratio 2.14
MDXG's Quick Ratio is ranked higher than
57% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 1.79 vs. MDXG: 2.14 )
Ranked among companies with meaningful Quick Ratio only.
MDXG' s Quick Ratio Range Over the Past 10 Years
Min: 0.07  Med: 3.16 Max: 14
Current: 2.14
0.07
14
Days Inventory 177.42
MDXG's Days Inventory is ranked lower than
68% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 130.04 vs. MDXG: 177.42 )
Ranked among companies with meaningful Days Inventory only.
MDXG' s Days Inventory Range Over the Past 10 Years
Min: 11.88  Med: 129.89 Max: 177.42
Current: 177.42
11.88
177.42
Days Sales Outstanding 100.04
MDXG's Days Sales Outstanding is ranked lower than
75% of the 272 Companies
in the Global Medical Devices industry.

( Industry Median: 68.94 vs. MDXG: 100.04 )
Ranked among companies with meaningful Days Sales Outstanding only.
MDXG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 74.94  Med: 99.25 Max: 104.76
Current: 100.04
74.94
104.76
Days Payable 128.81
MDXG's Days Payable is ranked higher than
80% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 59.71 vs. MDXG: 128.81 )
Ranked among companies with meaningful Days Payable only.
MDXG' s Days Payable Range Over the Past 10 Years
Min: 88.08  Med: 112.68 Max: 164.89
Current: 128.81
88.08
164.89

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.60
MDXG's 3-Year Average Share Buyback Ratio is ranked higher than
65% of the 218 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. MDXG: -1.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MDXG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -105.6  Med: -24.95 Max: -1.6
Current: -1.6
-105.6
-1.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 18.88
MDXG's Price-to-Net-Current-Asset-Value is ranked lower than
74% of the 206 Companies
in the Global Medical Devices industry.

( Industry Median: 6.88 vs. MDXG: 18.88 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
MDXG' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 12.98  Med: 16.81 Max: 135
Current: 18.88
12.98
135
Price-to-Tangible-Book 14.08
MDXG's Price-to-Tangible-Book is ranked lower than
81% of the 263 Companies
in the Global Medical Devices industry.

( Industry Median: 4.11 vs. MDXG: 14.08 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
MDXG' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 10.2  Med: 15.64 Max: 83.48
Current: 14.08
10.2
83.48
Price-to-Intrinsic-Value-Projected-FCF 7.15
MDXG's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
81% of the 129 Companies
in the Global Medical Devices industry.

( Industry Median: 2.23 vs. MDXG: 7.15 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
MDXG' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 5.5  Med: 11.29 Max: 28.12
Current: 7.15
5.5
28.12
Price-to-Median-PS-Value 0.51
MDXG's Price-to-Median-PS-Value is ranked higher than
89% of the 242 Companies
in the Global Medical Devices industry.

( Industry Median: 1.03 vs. MDXG: 0.51 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MDXG' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.39  Med: 1.04 Max: 10.38
Current: 0.51
0.39
10.38
Price-to-Graham-Number 8.11
MDXG's Price-to-Graham-Number is ranked lower than
91% of the 138 Companies
in the Global Medical Devices industry.

( Industry Median: 2.19 vs. MDXG: 8.11 )
Ranked among companies with meaningful Price-to-Graham-Number only.
MDXG' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 4.16  Med: 6.24 Max: 13.1
Current: 8.11
4.16
13.1
Earnings Yield (Greenblatt) % 1.81
MDXG's Earnings Yield (Greenblatt) % is ranked lower than
53% of the 432 Companies
in the Global Medical Devices industry.

( Industry Median: 2.17 vs. MDXG: 1.81 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MDXG' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.1  Med: 1.9 Max: 2.9
Current: 1.81
0.1
2.9

More Statistics

Revenue (TTM) (Mil) $245.0
EPS (TTM) $ 0.11
Beta0.66
Short Percentage of Float31.23%
52-Week Range $6.64 - 11.90
Shares Outstanding (Mil)110.84

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 299 350
EPS ($) 0.31 0.34
EPS without NRI ($) 0.31 0.34
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for MDXG

Headlines

Articles On GuruFocus.com
MiMedx To Present At 5th Annual Cell & Gene Therapy Investor Day Apr 18 2017 
MiMedx Announces First Quarter 2017 Revenue to Exceed High End of Guidance Apr 13 2017 
The Use Of MiMedx Allografts From The Company's Multiple Product Families To Be Presented At SAWC Co Apr 05 2017 
Celleration Acquisition Just the Start of Alliqua’s M&A Strategy Feb 04 2015 

More From Other Websites
4 Stocks With Strong Technical Momentum Apr 21 2017
Harry Boxer’s momentum stocks to watch: 3 biotechs, 1 retailer Apr 19 2017
Four Stocks With Strong Technical Momentum, Including Sears Apr 19 2017
MiMedx To Present At 5th Annual Cell & Gene Therapy Investor Day Apr 18 2017
ETFs with exposure to MiMedx Group, Inc. : April 17, 2017 Apr 17 2017
MiMedx Group (MDXG) Catches Eye: Stock Jumps 8.5% in Session Apr 17 2017
MiMedx Announces First Quarter 2017 Revenue to Exceed High End of Guidance Apr 13 2017
The Use Of MiMedx Allografts From The Company's Multiple Product Families To Be Presented At SAWC... Apr 05 2017
MiMedx To Present At The 16th Annual Needham Healthcare Conference Mar 24 2017
MiMedx Announces The Addition Of Luis A. Aguilar To Its Board Of Directors Mar 19 2017
MiMedx To Present At Canaccord's 12th Annual Musculoskeletal Conference Mar 08 2017
MiMedx Group, Inc. :MDXG-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017 Mar 07 2017
MiMedx Group, Inc. breached its 50 day moving average in a Bearish Manner : MDXG-US : March 7, 2017 Mar 07 2017
MiMedx to Host Shareholder call on March 9, 2017 to present various strategic and tactical... Mar 02 2017
MiMedx Audit Committee Announces Completion Of Its Investigation Mar 01 2017
Edited Transcript of MDXG earnings conference call or presentation 23-Feb-17 3:30pm GMT Feb 24 2017
MiMedx Announces 2016 Record Results Feb 23 2017
MiMedx Announces Release Date for 2016 Full Year Results Feb 16 2017
Benefits Of MiMedx dHACM Allograft Chronicled In Multiple Articles In February 2017 Supplement... Feb 07 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)